广东众生药业股份有限公司关于控股子公司获得日本专利证书的公告

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received a patent certificate from the Japan Patent Office for a key compound related to its oral antiviral drug, Lairuitai Tablets, which is the first oral monotherapy for COVID-19 [1][2]. Group 1: Patent Details - The patent is for "ケトアミド誘導体およびその用途" (Ketamide derivatives and their applications) with patent number 7735531, applied on September 5, 2022, and valid for 20 years from the application date [1]. - The patent is considered a core patent for Lairuitai Tablets, which effectively reduces viral load, shortens the time to viral clearance, and alleviates clinical symptoms [1]. Group 2: Market Implications - The acquisition of this core patent enhances the company's intellectual property protection system and supports the promotion of Lairuitai Tablets in overseas target markets [2]. - The patent authorization is not expected to have a significant impact on the company's short-term financial status or operating performance [2].